EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

IGF2BP3 Orchestrates Metabolic Reprogramming via Stabilizing m6A-Modified PLK1 mRNA to Promote Hepatocellular Carcinoma Progression

Guohua Ji, Ruining Liu, Yuli Ding, Shuang Wu, Yuzhou Luo, Cize Gao, Xiaobo Cui

International Journal of Molecular Sciences · 2026

DOI: 10.3390/ijms27209245 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Guohua Ji und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Genetics, School of Basic Medical Sciences, Harbin Medical University, Harbin 150081, China. Hauptthemen laut MEDLINE: Cell Cycle Proteins, Liver Neoplasms, Protein Serine-Threonine Kinases, Carcinoma, Hepatocellular. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Heilongjiang Province of China, HMU Marshal Initiative Funding.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Epigenetic dysregulation, particularly N6-methyladenosine (m6A) modification, drives hepatocellular carcinoma (HCC) progression, yet the oncogenic role of the m6A reader IGF2BP3 remains incompletely understood. This study aimed to elucidate the functional contributions and molecular mechanisms of IGF2BP3 in HCC. Multi-omics databases and tissue microarrays were employed to evaluate IGF2BP3 and PLK1 expression, clinicopathological associations, and prognostic value via Kaplan–Meier, Cox regression, and ROC analyses. Molecular interactions were probed by RIP, luciferase reporter, MeRIP, dot blot, and actinomycin D assays. In vitro gain/loss-of-function experiments measured glycolytic metabolites, extracellular acidification rate (ECAR), oxygen consumption rate (OCR), mitochondrial mass/charge, ROS, and key proteins of glycolysis and oxidative phosphorylation (OXPHOS). Both IGF2BP3 and PLK1 were significantly upregulated in HCC versus adjacent non-tumor tissues, correlating positively with advanced clinical stage, higher tumor grade, and poorer overall survival. In the TCGA-LIHC discovery cohort, each showed an independent prognostic association with unfavorable outcomes after adjustment for established clinical covariates. PLK1 mRNA was validated to carry m6A modifications and directly bind IGF2BP3, an interaction abolished by cycloleucine. Functionally, IGF2BP3 upregulated m6A-modified PLK1 by enhancing its mRNA stability, leading to elevated HK2 expression, increased glucose-6-phosphate and lactate levels, and enhanced ECAR, while suppressing mitochondrial respiratory chain complexes, ROS production, and OCR. In conclusion, IGF2BP3 is overexpressed in HCC and tightly associated with aggressive clinicopathological features and adverse outcomes. Altogether, these findings suggest that IGF2BP3 may enhance the stability of the m6A-modified PLK1 transcript, orchestrating a metabolic rewiring from oxidative phosphorylation to glycolysis, revealing a potential IGF2BP3–m6A–PLK1 axis driving HCC aggressiveness and offering potential therapeutic targets for precision intervention.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cell Cycle ProteinsLiver NeoplasmsProtein Serine-Threonine KinasesCarcinoma, HepatocellularProto-Oncogene ProteinsRNA-Binding ProteinsHumansPolo-Like Kinase 1Metabolic ReprogrammingGene Expression Regulation, NeoplasticRNA, MessengerMaleFemaleCell Line, TumorRNA MethylationDisease ProgressionPrognosisGlycolysisRNA StabilityOxidative Phosphorylation

Stichwörter der Autor:innen

IGF2BP3PLK1glycolysishepatocellular carcinomam6A

Substanzen

Polo-Like Kinase 1Cell Cycle ProteinsProtein Serine-Threonine KinasesProto-Oncogene ProteinsRNA-Binding ProteinsIGF2BP3 protein, humanRNA, Messenger

Autor:innen und Institutionen

  • Department of Medical Genetics, School of Basic Medical Sciences, Harbin Medical University, Harbin 150081, China.
  • Key Laboratory of Preservation of Human Genetic Resources and Disease Control in China (Harbin Medical University), Ministry of Education, Harbin 150081, China.

Förderung

  • Natural Science Foundation of Heilongjiang Province of China
  • HMU Marshal Initiative Funding

Zitieren

APA

Ji, G., Liu, R., Ding, Y., Wu, S., Luo, Y., Gao, C., & Cui, X. (2026). IGF2BP3 Orchestrates Metabolic Reprogramming via Stabilizing m6A-Modified PLK1 mRNA to Promote Hepatocellular Carcinoma Progression. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27209245

Vancouver

Ji G, Liu R, Ding Y, Wu S, Luo Y, Gao C, et al. IGF2BP3 Orchestrates Metabolic Reprogramming via Stabilizing m6A-Modified PLK1 mRNA to Promote Hepatocellular Carcinoma Progression. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27209245

BibTeX
@article{Ji2026,
  author = {Ji, Guohua and Liu, Ruining and Ding, Yuli and Wu, Shuang and Luo, Yuzhou and Gao, Cize and Cui, Xiaobo},
  title = {IGF2BP3 Orchestrates Metabolic Reprogramming via Stabilizing m6A-Modified PLK1 mRNA to Promote Hepatocellular Carcinoma Progression},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  doi = {10.3390/ijms27209245}
}
Kostenlos starten →